fluorouracil has been researched along with Cancer of Gallbladder in 127 studies
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Patients with gallbladder cancer or cholangiocarcinoma were treated with the combination of gemcitabine 1,000 mg/m(2) IV over 100 min on days 1 and 8 and capecitabine 650 mg/m(2) BID PO on days 1-14, administered every 21 days." | 9.15 | A phase II trial of gemcitabine and capecitabine in patients with unresectable or metastatic gallbladder cancer or cholangiocarcinoma: Southwest Oncology Group study S0202. ( Ahmad, SA; Blanke, CD; El-Khoueiry, AB; Gold, PJ; Holcombe, RF; Iqbal, S; Lenz, HJ; Messino, MJ; Rankin, C, 2011) |
| " levofolinic acid and oral hydroxyurea on a weekly schedule is well tolerated by the vast majority of patients with locally advanced and/or metastatic carcinoma of the pancreas or the gallbladder." | 9.08 | Treatment of advanced adenocarcinomas of the exocrine pancreas and the gallbladder with 5-fluorouracil, high dose levofolinic acid and oral hydroxyurea on a weekly schedule. Results of a multicenter study of the Southern Italy Oncology Group (G.O.I.M.). ( Colucci, G; Fortunato, S; Gebbia, N; Gebbia, V; Giotta, F; Giuseppe, S; Majello, E; Pezzella, G; Riccardi, F; Testa, A, 1996) |
| "The primary objective of this study was to determine the activity and safety of 3-weekly oxaliplatin combined with gemcitabine and oral capecitabine in the first-line treatment of advanced biliary tract cancer." | 7.81 | Three-weekly oxaliplatin combined with gemcitabine and capecitabine in the first-line treatment of patients with advanced biliary tract cancer. ( Fiaschi, AI; Francini, E; Laera, L; Marrelli, D; Petrioli, R; Roviello, F; Roviello, G, 2015) |
| "To investigate in vitro treatment with NVP-AEW541, a small molecule inhibitor of insulin-like growth factor-1 receptor (IGF-1R), in biliary tract cancer (BTC), since this disease is associated with a poor prognosis due to wide resistance to chemotherapeutic agents and radiotherapy." | 7.76 | Treatment of biliary tract cancer with NVP-AEW541: mechanisms of action and resistance. ( Lorenz, J; Mössner, J; Wiedmann, M; Wolf, S, 2010) |
| "The authors performed a retrospective analysis of all patients with hepatocellular carcinoma (HCC), cholangiocarcinoma (CCA), or gallbladder carcinoma (GBC) who were ever treated with oral capecitabine." | 7.72 | Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma. ( Aguayo, A; Brown, TD; Charnsangavej, C; Curley, SA; Ellis, LM; Hassan, MM; Lozano, RD; Nooka, AK; Patt, YZ; Schnirer, II; Vauthey, JN; Wolff, RA, 2004) |
| "The present cases demonstrate that high-dose 5-fluorouracil-based chemotherapy not only induces a colitis but also may involve the upper small intestine tract." | 7.71 | [5-Fluorouracil-induced colitis--a review based upon consideration of 6 cases]. ( Hotz, J; Madisch, A; Marquard, F; Stolte, M; Wiedbrauck, F, 2002) |
| "The adjuvant therapy (AT) for biliary tract cancer (BTC) patients after surgery has always been controversial." | 6.82 | The efficacy and safety of 5-fluorouracil based adjuvant therapy in resected biliary tract cancer: A systematic review and meta-analysis. ( Cheng, Q; Gong, S; Guo, T; Lei, C; Lu, T; Lv, K; Song, S; Tian, H; Yang, K; Yang, W, 2022) |
| "The role of postoperative therapy in extrahepatic cholangiocarcinoma (EHCC) or gallbladder carcinoma (GBCA) is unknown." | 6.80 | SWOG S0809: A Phase II Intergroup Trial of Adjuvant Capecitabine and Gemcitabine Followed by Radiotherapy and Concurrent Capecitabine in Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma. ( Alberts, SR; Ben-Josef, E; Blanke, CD; Corless, CL; Dawson, LA; El-Khoueiry, AB; Guthrie, KA; Lowy, AM; Micetich, KC; Siegel, AB; Thomas, CR; Thomas, MB; Zalupski, MM, 2015) |
| "Capecitabine was administered orally at a dose of 1,000 mg/m(2) twice a day for 14 days, followed by a 1-week rest period." | 5.38 | Capecitabine plus cisplatin as first-line chemotherapy for advanced biliary tract cancer: a retrospective single-center study. ( Han, SS; Hong, EK; Kim, CM; Kim, HB; Kim, TH; Koh, YH; Lee, WJ; Park, JW; Park, SJ; Woo, SM, 2012) |
| "Patients with gallbladder cancer or cholangiocarcinoma were treated with the combination of gemcitabine 1,000 mg/m(2) IV over 100 min on days 1 and 8 and capecitabine 650 mg/m(2) BID PO on days 1-14, administered every 21 days." | 5.15 | A phase II trial of gemcitabine and capecitabine in patients with unresectable or metastatic gallbladder cancer or cholangiocarcinoma: Southwest Oncology Group study S0202. ( Ahmad, SA; Blanke, CD; El-Khoueiry, AB; Gold, PJ; Holcombe, RF; Iqbal, S; Lenz, HJ; Messino, MJ; Rankin, C, 2011) |
| " The authors evaluated 6-month survival, response, and toxicity associated with a combination of gemcitabine, 5-fluorouracil (5-FU), and leucovorin (LV) in patients with unresectable or metastatic biliary tract or gallbladder adenocarcinoma (ACA)." | 5.11 | Gemcitabine, 5-fluorouracil, and leucovorin in advanced biliary tract and gallbladder carcinoma: a North Central Cancer Treatment Group phase II trial. ( Al-Khatib, H; Alberts, SR; Burgart, L; Cera, PJ; Finch, TR; Flynn, PJ; Knost, JA; Levitt, R; Mahoney, MR; Tschetter, LK; Windschitl, HE, 2005) |
| "Biweekly intravenous infusions of low-dose cisplatin (CDDP) and 5-fluorouracil (5-FU) were evaluated in 80 patients with advanced or recurrent gastric, colorectal, pancreatic or gallbladder adenocarcinoma." | 5.09 | [Biweekly low-dose cisplatin and 5-fluorouracil combination chemotherapy for advanced gastrointestinal carcinoma]. ( Kamata, T; Kanno, M; Koyasaki, N; Morita, A; Nakamoto, A; Onishi, I; Takeda, T, 2000) |
| " levofolinic acid and oral hydroxyurea on a weekly schedule is well tolerated by the vast majority of patients with locally advanced and/or metastatic carcinoma of the pancreas or the gallbladder." | 5.08 | Treatment of advanced adenocarcinomas of the exocrine pancreas and the gallbladder with 5-fluorouracil, high dose levofolinic acid and oral hydroxyurea on a weekly schedule. Results of a multicenter study of the Southern Italy Oncology Group (G.O.I.M.). ( Colucci, G; Fortunato, S; Gebbia, N; Gebbia, V; Giotta, F; Giuseppe, S; Majello, E; Pezzella, G; Riccardi, F; Testa, A, 1996) |
| "The primary objective of this study was to determine the activity and safety of 3-weekly oxaliplatin combined with gemcitabine and oral capecitabine in the first-line treatment of advanced biliary tract cancer." | 3.81 | Three-weekly oxaliplatin combined with gemcitabine and capecitabine in the first-line treatment of patients with advanced biliary tract cancer. ( Fiaschi, AI; Francini, E; Laera, L; Marrelli, D; Petrioli, R; Roviello, F; Roviello, G, 2015) |
| "To investigate in vitro treatment with NVP-AEW541, a small molecule inhibitor of insulin-like growth factor-1 receptor (IGF-1R), in biliary tract cancer (BTC), since this disease is associated with a poor prognosis due to wide resistance to chemotherapeutic agents and radiotherapy." | 3.76 | Treatment of biliary tract cancer with NVP-AEW541: mechanisms of action and resistance. ( Lorenz, J; Mössner, J; Wiedmann, M; Wolf, S, 2010) |
| "The authors performed a retrospective analysis of all patients with hepatocellular carcinoma (HCC), cholangiocarcinoma (CCA), or gallbladder carcinoma (GBC) who were ever treated with oral capecitabine." | 3.72 | Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma. ( Aguayo, A; Brown, TD; Charnsangavej, C; Curley, SA; Ellis, LM; Hassan, MM; Lozano, RD; Nooka, AK; Patt, YZ; Schnirer, II; Vauthey, JN; Wolff, RA, 2004) |
| "The present cases demonstrate that high-dose 5-fluorouracil-based chemotherapy not only induces a colitis but also may involve the upper small intestine tract." | 3.71 | [5-Fluorouracil-induced colitis--a review based upon consideration of 6 cases]. ( Hotz, J; Madisch, A; Marquard, F; Stolte, M; Wiedbrauck, F, 2002) |
| "Four patients with gallbladder cancer and two with bile duct cancer were treated with mitomycin C, carboquone, 5-fluorouracil and OK-432 (MQF-OK therapy) plus tegafur (FT) or UFT." | 3.67 | [MQF-FT and MQF-UFT in gallbladder and bile duct cancer]. ( Fukushi, G; Itoh, T; Kimura, M; Kimura, T; Kishibe, T; Saitoh, S; Sakata, Y; Suzuki, H; Tamura, Y; Tsushima, K, 1988) |
| "The adjuvant therapy (AT) for biliary tract cancer (BTC) patients after surgery has always been controversial." | 2.82 | The efficacy and safety of 5-fluorouracil based adjuvant therapy in resected biliary tract cancer: A systematic review and meta-analysis. ( Cheng, Q; Gong, S; Guo, T; Lei, C; Lu, T; Lv, K; Song, S; Tian, H; Yang, K; Yang, W, 2022) |
| "The role of postoperative therapy in extrahepatic cholangiocarcinoma (EHCC) or gallbladder carcinoma (GBCA) is unknown." | 2.80 | SWOG S0809: A Phase II Intergroup Trial of Adjuvant Capecitabine and Gemcitabine Followed by Radiotherapy and Concurrent Capecitabine in Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma. ( Alberts, SR; Ben-Josef, E; Blanke, CD; Corless, CL; Dawson, LA; El-Khoueiry, AB; Guthrie, KA; Lowy, AM; Micetich, KC; Siegel, AB; Thomas, CR; Thomas, MB; Zalupski, MM, 2015) |
| " Main adverse events grades 2/3/4 were (n): leukocytopenia 3/2/2, anemia 13/4/0, thrombocytopenia 3/1/0, nausea/vomiting 2/1/0, diarrhea 5/1/0, hand-foot-skin reaction 7/0/0." | 2.75 | Efficacy and safety of capecitabine in combination with docetaxel and mitomycin C in patients with pre-treated pancreatic, gallbladder, and bile duct carcinoma. ( Ernst, T; Hochhaus, A; Hofheinz, RD; Hofmann, WK; Kripp, M; Kruth, J; Lukan, N; Merx, K; Nissen, J, 2010) |
| "5-fluorouracil (5-FU) has been widely used for the treatment of gastrointestinal cancers." | 2.69 | [Preliminary clinical evaluation of low-dose CDDP and continuous 5-FU therapy for advanced gallbladder cancer]. ( Horimi, T; Morita, S; Shirasaka, T; Takahashi, I; Takamatsu, M; Takasaki, M; Tsuji, A, 2000) |
| "Seven patients with advanced gallbladder cancer were treated by arterial infusion chemotherapy." | 2.67 | [Evaluation of arterial infusion chemotherapy for advanced gallbladder cancer using implantable port]. ( Fujiwara, Y; Hata, Y; Higaki, T; Hisa, N; Kamiike, O; Morita, S; Yoshida, D; Yoshida, S, 1994) |
| "Three of 34 patients with bile duct cancer (1/12 [8%] on 5-FU, 0/10 on 5-FU + Stz, and 2/12 on 5-FU + MeCCNU) had objective response to treatment." | 2.65 | Eastern Cooperative Oncology Group experience with chemotherapy for inoperable gallbladder and bile duct cancer. ( Falkson, G; MacIntyre, JM; Moertel, CG, 1984) |
| "Most patients with unresectable biliary tract cancer develop obstructive jaundice, and biliary drainage is needed before any of the aforementioned treatments." | 2.48 | Role of chemotherapy in treatments for biliary tract cancer. ( Furuse, J; Kasuga, A; Kitamura, H; Nagashima, F; Takasu, A, 2012) |
| "The prognosis of patients with biliary tract cancer remains unsatisfactory even with surgery owing to the high recurrence rate." | 2.48 | Adjuvant chemotherapy for resectable biliary tract cancer: current status and future direction. ( Konishi, M, 2012) |
| "Gallbladder cancer is an aggressive tumor." | 2.46 | [Chemotherapy in gallbladder carcinoma]. ( Abahssain, H; Afchain, P; Errihani, H; Ismaili, N; Melas, N; Rabti, HM; Rahali, R, 2010) |
| " The purpose of this article is to review the available information on capecitabine with respect to clinical efficacy for tumors of the digestive tract, adverse-effect profile, documented drug interactions, dosage and administration, and future directions of ongoing research." | 2.45 | The role of capecitabine in the management of tumors of the digestive system. ( Gennatas, C; Gennatas, S; Michalaki, V, 2009) |
| "MEF2D was up-regulated in gallbladder cancer and associated with tumor size and clinical stage." | 1.51 | MiR-335 promotes cell proliferation by inhibiting MEF2D and sensitizes cells to 5-Fu treatment in gallbladder carcinoma. ( Chen, LC; Qian, JY; Wang, W; Zhang, Q, 2019) |
| "The aim of this retrospective study was to clarify the effectiveness of chemotherapy with gemcitabine combined with low-dose 5-fluorouracil and cisplatin (GFP) for advanced biliary carcinoma after hepatectomy." | 1.46 | Effect of Adjuvant Gemcitabine Combined with Low-dose 5-Fluorouracil and Cisplatin Chemotherapy for Advanced Biliary Carcinoma. ( Arakawa, Y; Ikemoto, T; Imura, S; Iwahashi, S; Morine, Y; Saito, YU; Shimada, M; Yamada, S, 2017) |
| "Combination therapy with 5-FU and interferon-α was safe and may improve the prognosis of advanced biliary carcinomas." | 1.42 | Intraarterial 5-fluorouracil and interferon therapy is safe and effective for nonresectable biliary tract adenocarcinoma. ( Kanda, M; Kawai, T; Obi, S; Sato, S; Sato, T; Sugimoto, T; Yashima, Y, 2015) |
| "Hispidulin was found to repress the expression of HIF-1α protein dose-dependently without affecting the HIF-1α mRNA expression." | 1.42 | Hispidulin inhibits proliferation and enhances chemosensitivity of gallbladder cancer cells by targeting HIF-1α. ( Gao, H; Han, M; Han, Y; Jiang, Q; Peng, J; Wang, C; Xie, J, 2015) |
| "Gallbladder cancer is the most common malignancy of the bile duct, with low 5-year survival rate and poor prognosis." | 1.40 | Cordycepin down-regulates multiple drug resistant (MDR)/HIF-1α through regulating AMPK/mTORC1 signaling in GBC-SD gallbladder cancer cells. ( Hong, DF; Hu, ZM; Huang, DS; Shang, MJ; Wu, WD; Zhang, CW; Zhao, DJ, 2014) |
| "The prognosis of unresectable biliary tract cancer has improved recently." | 1.39 | Improvement of prognosis for unresectable biliary tract cancer. ( Hirano, K; Isayama, H; Ito, Y; Kogure, H; Koike, K; Mizuno, S; Nakai, Y; Omata, M; Sasahira, N; Sasaki, T; Tada, M; Takahara, N; Toda, N; Yagioka, H; Yamamoto, N, 2013) |
| "Capecitabine was administered orally at a dose of 1,000 mg/m(2) twice a day for 14 days, followed by a 1-week rest period." | 1.38 | Capecitabine plus cisplatin as first-line chemotherapy for advanced biliary tract cancer: a retrospective single-center study. ( Han, SS; Hong, EK; Kim, CM; Kim, HB; Kim, TH; Koh, YH; Lee, WJ; Park, JW; Park, SJ; Woo, SM, 2012) |
| "Gallbladder cancer is a rare disease and it is associated with a poor clinical outcome and survival." | 1.37 | Evaluation of two modified ECF regimens in the treatment of advanced gallbladder cancer. ( Li, SG; Liu, YB; Quan, ZW; Shen, J; Shi, WB; Wang, JD; Wang, XF; Yang, Y; Zhou, XP; Zhuang, PY, 2011) |
| "Gallbladder cancer is a relatively uncommon gastrointestinal malignancy." | 1.36 | Adjuvant chemoradiation therapy in gallbladder cancer. ( Cho, SY; Han, SS; Kim, SH; Kim, TH; Kim, YK; Lee, KW; Lee, WJ; Park, SJ; Woo, SM, 2010) |
| "Patients with cholangiocarcinoma or gallbladder cancer have poor overall prognosis and their management is often complex." | 1.36 | Outcome of patients receiving chemotherapy for advanced biliary tract or gallbladder carcinoma. ( Adham, M; Bancel, B; Baulieux, J; Cassier, PA; Lombard-Bohas, C; Ponchon, T; Scoazec, JY; Souquet, JC; Thevenet, C; Walter, T, 2010) |
| "Twenty-nine patients with pancreatic cancer (PC) and 43 with biliary tract cancer (BTC; 27 cases of bile duct cancer, 8 of gallbladder cancer and 8 of cancer of the papillary area) were included." | 1.35 | Thymidylate synthase and dihydropyrimidine dehydrogenase are upregulated in pancreatic and biliary tract cancers. ( Kubota, K; Sawada, T; Shimoda, M, 2009) |
| "We report a case of advanced gallbladder cancer for which the anticancer drug S-1 was effective." | 1.35 | Successful treatment of advanced gallbladder cancer with an anticancer drug S-1: assessment based on intratumoral gene. ( Aiba, K; Ishida, Y; Kawakami, M; Kitajima, K; Kobayashi, S; Shiba, H; Uwagawa, T; Yanaga, K, 2008) |
| "The incidence of gallbladder cancer (GBC) in the US is 1." | 1.35 | Gallbladder cancer (GBC): 10-year experience at Memorial Sloan-Kettering Cancer Centre (MSKCC). ( Abou-Alfa, GK; Blumgart, LH; Capanu, M; D'Angelica, M; Dematteo, RP; Duffy, A; Fong, Y; Huitzil, D; Jarnagin, W; O'Reilly, EM, 2008) |
| "Hamsters and SCID and BALB/c mice harboring peritoneal dissemination of gallbladder, gastric or colon cancer cells were treated with G207, 5-fluorouracil (5FU), or surgical resection alone, or G207 combined with 5FU or surgery." | 1.33 | Enhanced efficacy of conditionally replicating herpes simplex virus (G207) combined with 5-fluorouracil and surgical resection in peritoneal cancer dissemination models. ( Cohen, JB; Glorioso, JC; Kuroki, S; Nakano, K; Tanaka, M; Todo, T; Yamaguchi, K; Zhao, G, 2005) |
| "Unresectable advanced gall bladder cancer has a very poor prognosis." | 1.33 | [Two cases of successful local control with intermittent hepatic arterial infusion therapy using 5-FU and external radiation therapy for unresectable advanced gall bladder cancer]. ( Aihara, T; Kim, C; Miki, H; Nakata, K; Ohzato, H; Okada, K; Okamura, S; Sugimoto, K; Takatsuka, Y; Takiuchi, D; Tamura, S; Tomita, N, 2005) |
| "The prognosis of unresectable advanced gallbladder cancer is extremely poor." | 1.32 | [A case of successful treatment with combined 5-fluorouracil, adriamycin, cisplatin (FAP) therapy followed by Gemcitabine, UFT therapy and intra-arterial FAP therapy for unresectable advanced gallbladder cancer]. ( Dono, K; Hashimoto, K; Kubota, M; Marubashi, S; Miyamoto, A; Monden, M; Nagano, H; Nakamori, S; Sakon, M; Takahashi, H; Umeshita, K; Yamamoto, S, 2004) |
| "Nine of these 18 patients had bile duct cancer, seven had gallbladder cancer, and two had cancer of the papilla of Vater." | 1.32 | [Adjuvant arterial infusion chemotherapy for patients with biliary cancer]. ( Hasuike, Y; Kashiwazaki, M; Takeda, Y; Tsujinaka, T, 2004) |
| "Gallbladder cancer is generally associated with a poor prognosis, being local recurrence the main pattern of failure." | 1.32 | [Neoadjuvant chemoradiotherapy in gallbladder cancer]. ( Burgos, L; de Aretxabala, X; Losada, H; Mora, J; Quijada, I; Roa, I; Roa, JC; Yáñez, E, 2004) |
| "The diagnosis was advanced gall bladder cancer of Stage IVa (S2, N3, P0, H0, Hinf1, Dinf1)." | 1.31 | [A case of inoperable advanced gall bladder cancer responding to intra-arterial infusion of 5-fluorouracil (5-FU) and leucovorin (LV)]. ( Kim, R; Miyahara, E; Ohta, K; Sawamura, A; Toge, T, 2001) |
| "A 50-year-old man with gallbladder cancer was treated by extended cholecystectomy and regional lymph node dissection." | 1.30 | [A case of recurrent gallbladder cancer with marked response to arterial infusion chemotherapy and transarterial embolization]. ( Ino, M; Noda, H; Takahashi, S; Takeuchi, S; Tanaka, T; Tateoka, H; Yokoyama, M, 1997) |
| "Although gallbladder cancer (GBC) is believed to be chemoresistant, the effectiveness of chemotherapy against lymph node metastasis has been reported." | 1.30 | Lymph node recurrence of gallbladder carcinoma successfully managed by systemic chemotherapy with 5-fluorouracil and mitomycin C: report of a 5-year survivor. ( Hatakeyama, K; Ohtani, T; Shirai, Y; Tsukada, K, 1997) |
| " Furthermore, the effectiveness of this therapy is greatly anticipated for the unresectable abdominal cancer, evaluating the selection of anti-cancer drugs and their administration dosage etc." | 1.30 | [Aortic stop flow and hypoxic perfusion chemotherapy for unresectable gallbladder cancer]. ( Aoki, T; Asami, K; Inoue, K; Kasuya, K; Koyanagi, Y; Masuhara, S; Ozawa, T; Tsuchida, A; Uda, O, 1998) |
| "Gallbladder cancer is well known as a chemoresistant cancer, whereas the higher response rate and the longer survival were achieved with HAI." | 1.29 | [Study of hepatic arterial chemoinfusion with continuous CDDP, 5-FU low dose administration for advanced gallbladder cancer]. ( Fukuda, S; Isomoto, H; Kinoshita, H; Nakayama, T; Okuda, K; Tanaka, M; Yoshida, T, 1996) |
| "In the case of gall bladder cancer cell line (NOZ), combination of adriamycin and hyperthermia showed more effective inhibition for cell proliferation than MMC + hyperthermia and 5-FU + hyperthermia." | 1.28 | [Combination therapy of hyperthermia and other methods in liver and bile tract cancers--evaluation of these methods using cancer cell lines in vitro]. ( Fujise, K; Hasumura, S; Homma, S; Kameda, H; Matsuura, T; Nagamori, S; Niiya, M; Shimizu, K; Sujino, H, 1989) |
| "Allopurinol has been shown to ameliorate the myelotoxicity of 5-fluorouracil (5-FU) given as an infusion." | 1.27 | Failure of allopurinol to provide clinically significant protection against the hematologic toxicity of a bolus 5-FU schedule. ( Ahmann, FR; Garewal, H, 1986) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 24 (18.90) | 18.7374 |
| 1990's | 16 (12.60) | 18.2507 |
| 2000's | 46 (36.22) | 29.6817 |
| 2010's | 38 (29.92) | 24.3611 |
| 2020's | 3 (2.36) | 2.80 |
| Authors | Studies |
|---|---|
| Lai, J | 1 |
| Yang, S | 1 |
| Lin, Z | 1 |
| Huang, W | 1 |
| Li, X | 2 |
| Li, R | 1 |
| Tan, J | 1 |
| Wang, W | 4 |
| Chen, LC | 1 |
| Qian, JY | 1 |
| Zhang, Q | 1 |
| Ramaswamy, A | 1 |
| Ostwal, V | 1 |
| Sharma, A | 2 |
| Bhargava, P | 1 |
| Srinivas, S | 1 |
| Goel, M | 1 |
| Patkar, S | 1 |
| Mandavkar, S | 1 |
| Jadhav, P | 1 |
| Parulekar, M | 1 |
| Choudhari, A | 1 |
| Gupta, S | 1 |
| Song, S | 1 |
| Yang, W | 1 |
| Tian, H | 1 |
| Gong, S | 1 |
| Lei, C | 1 |
| Lv, K | 1 |
| Lu, T | 1 |
| Cheng, Q | 1 |
| Yang, K | 1 |
| Guo, T | 1 |
| Morine, Y | 1 |
| Shimada, M | 1 |
| Ikemoto, T | 1 |
| Arakawa, Y | 1 |
| Iwahashi, S | 1 |
| Saito, YU | 1 |
| Yamada, S | 1 |
| Imura, S | 1 |
| Zhan, M | 1 |
| Yang, RM | 1 |
| Wang, H | 1 |
| He, M | 1 |
| Chen, W | 2 |
| Xu, SW | 1 |
| Yang, LH | 1 |
| Liu, Q | 1 |
| Long, MM | 1 |
| Wang, J | 1 |
| Hu, Z | 1 |
| Huang, Y | 1 |
| Zheng, H | 1 |
| Sun, Q | 1 |
| Yang, Q | 1 |
| Zhang, Y | 1 |
| Zhang, L | 1 |
| Bisello, S | 1 |
| Buwenge, M | 1 |
| Palloni, A | 1 |
| Autorino, R | 1 |
| Cellini, F | 1 |
| Macchia, G | 1 |
| Deodato, F | 1 |
| Cilla, S | 1 |
| Brandi, G | 1 |
| Tagliaferri, L | 1 |
| Cammelli, S | 1 |
| Valentini, V | 1 |
| Morganti, AG | 1 |
| Mattiucci, GC | 1 |
| Geng, ZM | 1 |
| Zhang, M | 1 |
| Pan, XT | 1 |
| Wang, L | 1 |
| Moretto, R | 1 |
| Raimondo, L | 1 |
| De Stefano, A | 1 |
| Cella, CA | 1 |
| Matano, E | 1 |
| De Placido, S | 1 |
| Carlomagno, C | 1 |
| Wu, WD | 1 |
| Hu, ZM | 1 |
| Shang, MJ | 1 |
| Zhao, DJ | 1 |
| Zhang, CW | 1 |
| Hong, DF | 1 |
| Huang, DS | 1 |
| Fiteni, F | 1 |
| Jary, M | 1 |
| Monnien, F | 1 |
| Nguyen, T | 1 |
| Beohou, E | 1 |
| Demarchi, M | 1 |
| Dobi, E | 1 |
| Fein, F | 1 |
| Cleau, D | 1 |
| Fratté, S | 1 |
| Nerich, V | 1 |
| Bonnetain, F | 1 |
| Pivot, X | 1 |
| Borg, C | 1 |
| Kim, S | 1 |
| Gao, H | 1 |
| Xie, J | 1 |
| Peng, J | 1 |
| Han, Y | 1 |
| Jiang, Q | 1 |
| Han, M | 1 |
| Wang, C | 1 |
| Yashima, Y | 1 |
| Sato, S | 1 |
| Kawai, T | 1 |
| Sugimoto, T | 1 |
| Sato, T | 3 |
| Kanda, M | 1 |
| Obi, S | 1 |
| Petrioli, R | 1 |
| Roviello, G | 1 |
| Fiaschi, AI | 1 |
| Laera, L | 1 |
| Roviello, F | 1 |
| Marrelli, D | 1 |
| Francini, E | 1 |
| Sirohi, B | 1 |
| Rastogi, S | 1 |
| Singh, A | 1 |
| Sheth, V | 1 |
| Dawood, S | 1 |
| Talole, S | 1 |
| Ramadwar, M | 1 |
| Kulkarni, S | 1 |
| Shrikhande, SV | 1 |
| Ben-Josef, E | 1 |
| Guthrie, KA | 1 |
| El-Khoueiry, AB | 2 |
| Corless, CL | 1 |
| Zalupski, MM | 1 |
| Lowy, AM | 1 |
| Thomas, CR | 1 |
| Alberts, SR | 2 |
| Dawson, LA | 1 |
| Micetich, KC | 1 |
| Thomas, MB | 1 |
| Siegel, AB | 1 |
| Blanke, CD | 2 |
| Dodagoudar, C | 1 |
| Doval, DC | 1 |
| Mahanta, A | 1 |
| Goel, V | 1 |
| Upadhyay, A | 1 |
| Goyal, P | 1 |
| Talwar, V | 1 |
| Singh, S | 1 |
| John, MC | 1 |
| Tiwari, S | 1 |
| Patnaik, N | 1 |
| Go, SI | 1 |
| Kim, YS | 1 |
| Hwang, IG | 1 |
| Kim, EY | 1 |
| Oh, SY | 1 |
| Ji, JH | 1 |
| Song, HN | 1 |
| Park, SH | 1 |
| Park, JO | 1 |
| Kang, JH | 1 |
| Li, Q | 1 |
| Mou, LJ | 1 |
| Tao, L | 1 |
| Sun, XT | 1 |
| Xia, XF | 1 |
| Wu, XY | 1 |
| Shi, XL | 1 |
| Shibata, T | 2 |
| Kokubu, A | 1 |
| Gotoh, M | 1 |
| Ojima, H | 1 |
| Ohta, T | 1 |
| Yamamoto, M | 1 |
| Hirohashi, S | 1 |
| Duffy, A | 1 |
| Capanu, M | 1 |
| Abou-Alfa, GK | 1 |
| Huitzil, D | 1 |
| Jarnagin, W | 1 |
| Fong, Y | 2 |
| D'Angelica, M | 1 |
| Dematteo, RP | 1 |
| Blumgart, LH | 1 |
| O'Reilly, EM | 1 |
| Kitajima, K | 1 |
| Kobayashi, S | 1 |
| Shiba, H | 1 |
| Uwagawa, T | 1 |
| Ishida, Y | 1 |
| Aiba, K | 1 |
| Kawakami, M | 1 |
| Yanaga, K | 1 |
| Yoshida, N | 1 |
| Kochi, M | 1 |
| Funada, T | 1 |
| Mamiya, T | 1 |
| Ohkubo, R | 1 |
| Kaiga, T | 1 |
| Takayama, T | 1 |
| Gennatas, C | 1 |
| Michalaki, V | 1 |
| Gennatas, S | 1 |
| Gold, DG | 1 |
| Miller, RC | 1 |
| Haddock, MG | 2 |
| Gunderson, LL | 3 |
| Quevedo, F | 1 |
| Donohue, JH | 1 |
| Bhatia, S | 1 |
| Nagorney, DM | 2 |
| Shimoda, M | 1 |
| Sawada, T | 1 |
| Kubota, K | 1 |
| Azad, A | 1 |
| Chionh, F | 1 |
| Jayarajan, J | 1 |
| Wagner, AD | 1 |
| Buechner-Steudel, P | 1 |
| Moehler, M | 1 |
| Schmalenberg, H | 1 |
| Behrens, R | 1 |
| Fahlke, J | 1 |
| Wein, A | 2 |
| Behl, S | 1 |
| Kuss, O | 1 |
| Kleber, G | 1 |
| Fleig, WE | 1 |
| Wolf, S | 1 |
| Lorenz, J | 1 |
| Mössner, J | 1 |
| Wiedmann, M | 1 |
| Louvet, C | 1 |
| Tournigand, C | 1 |
| Chang, PY | 1 |
| Cheng, MF | 1 |
| Lee, HS | 1 |
| Hsieh, CB | 1 |
| Yao, NS | 1 |
| Kruth, J | 1 |
| Nissen, J | 1 |
| Ernst, T | 1 |
| Kripp, M | 1 |
| Lukan, N | 1 |
| Merx, K | 1 |
| Hofmann, WK | 1 |
| Hochhaus, A | 1 |
| Hofheinz, RD | 1 |
| Cassier, PA | 1 |
| Thevenet, C | 1 |
| Walter, T | 1 |
| Baulieux, J | 1 |
| Scoazec, JY | 1 |
| Bancel, B | 1 |
| Adham, M | 1 |
| Souquet, JC | 1 |
| Ponchon, T | 1 |
| Lombard-Bohas, C | 1 |
| Manterola, C | 1 |
| Vial, M | 1 |
| Roa, JC | 3 |
| Cho, SY | 1 |
| Kim, SH | 1 |
| Park, SJ | 2 |
| Han, SS | 2 |
| Kim, YK | 1 |
| Lee, KW | 1 |
| Lee, WJ | 2 |
| Woo, SM | 2 |
| Kim, TH | 2 |
| Dwary, AD | 1 |
| Mohanti, BK | 1 |
| Deo, SV | 1 |
| Pal, S | 1 |
| Sreenivas, V | 1 |
| Raina, V | 1 |
| Shukla, NK | 1 |
| Thulkar, S | 1 |
| Garg, P | 1 |
| Chaudhary, SP | 1 |
| Shi, C | 1 |
| Tian, R | 1 |
| Wang, M | 1 |
| Wang, X | 2 |
| Jiang, J | 1 |
| Zhang, Z | 1 |
| He, Z | 1 |
| Gong, W | 1 |
| Qin, R | 1 |
| Abahssain, H | 1 |
| Afchain, P | 1 |
| Melas, N | 1 |
| Ismaili, N | 1 |
| Rahali, R | 1 |
| Rabti, HM | 1 |
| Errihani, H | 1 |
| Wang, JD | 1 |
| Shi, WB | 1 |
| Shen, J | 1 |
| Zhuang, PY | 1 |
| Quan, ZW | 1 |
| Wang, XF | 1 |
| Zhou, XP | 1 |
| Li, SG | 1 |
| Liu, YB | 1 |
| Yang, Y | 1 |
| Iqbal, S | 1 |
| Rankin, C | 1 |
| Lenz, HJ | 1 |
| Gold, PJ | 1 |
| Ahmad, SA | 1 |
| Messino, MJ | 1 |
| Holcombe, RF | 1 |
| Meng, H | 1 |
| Wang, ZH | 1 |
| Wang, Y | 1 |
| Zhang, ZT | 1 |
| González, ME | 1 |
| Giannini, OH | 1 |
| González, P | 1 |
| Saldaña, B | 1 |
| Konishi, M | 1 |
| Kim, K | 1 |
| Chie, EK | 1 |
| Jang, JY | 1 |
| Kim, SW | 1 |
| Han, SW | 1 |
| Oh, DY | 1 |
| Im, SA | 1 |
| Kim, TY | 1 |
| Bang, YJ | 1 |
| Ha, SW | 1 |
| Furuse, J | 2 |
| Kasuga, A | 1 |
| Takasu, A | 1 |
| Kitamura, H | 1 |
| Nagashima, F | 1 |
| Koh, YH | 1 |
| Kim, HB | 1 |
| Hong, EK | 1 |
| Park, JW | 1 |
| Kim, CM | 1 |
| Croitoru, A | 1 |
| Gramaticu, I | 1 |
| Dinu, I | 1 |
| Gheorghe, L | 1 |
| Alexandrescu, S | 1 |
| Buica, F | 1 |
| Luca, I | 1 |
| Becheanu, G | 1 |
| Herlea, V | 1 |
| Simionov, I | 1 |
| Hrehoret, D | 1 |
| Lupescu, I | 1 |
| Popescu, I | 1 |
| Diculescu, M | 1 |
| Sasaki, T | 2 |
| Isayama, H | 1 |
| Nakai, Y | 1 |
| Takahara, N | 1 |
| Sasahira, N | 1 |
| Kogure, H | 1 |
| Mizuno, S | 1 |
| Yagioka, H | 1 |
| Ito, Y | 1 |
| Yamamoto, N | 1 |
| Hirano, K | 1 |
| Toda, N | 1 |
| Tada, M | 1 |
| Omata, M | 1 |
| Koike, K | 1 |
| Bourmèche, M | 1 |
| Ben Salah, H | 1 |
| Kallel, M | 1 |
| Beyrouti, MI | 1 |
| Makni, S | 1 |
| Boudawara, T | 1 |
| Frikha, M | 1 |
| Daoud, J | 1 |
| Matsukuma, A | 1 |
| Araki, K | 1 |
| Kawaguchi, H | 1 |
| Kusumoto, H | 1 |
| Haraguchi, M | 1 |
| Takada, T | 2 |
| Amano, H | 1 |
| Yasuda, H | 1 |
| Nimura, Y | 1 |
| Matsushiro, T | 2 |
| Kato, H | 2 |
| Nagakawa, T | 1 |
| Nakayama, T | 2 |
| Boxberger, F | 1 |
| Jüngert, B | 1 |
| Brueckl, V | 1 |
| Brueckl, WM | 1 |
| Hautmann, M | 1 |
| Hohenberger, W | 1 |
| Hahn, EG | 1 |
| Misra, S | 1 |
| Chaturvedi, A | 1 |
| Misra, NC | 1 |
| Sharma, ID | 1 |
| Malik, IA | 1 |
| Aziz, Z | 1 |
| Kim, TW | 1 |
| Chang, HM | 1 |
| Kang, HJ | 1 |
| Lee, JR | 1 |
| Ryu, MH | 1 |
| Ahn, JH | 1 |
| Kim, JH | 1 |
| Lee, JS | 1 |
| Kang, YK | 1 |
| REITEMEIER, RJ | 3 |
| MOERTEL, CG | 4 |
| BLACKBURN, CM | 1 |
| HAHN, RG | 2 |
| Oku, T | 1 |
| Yoshizaki, N | 1 |
| Waga, E | 1 |
| Sumiyoshi, T | 1 |
| Ohira, N | 1 |
| Nishihori, Y | 1 |
| Ohi, M | 1 |
| Kondo, H | 2 |
| Motohara, T | 1 |
| Yoshida, Y | 1 |
| Knox, JJ | 3 |
| Hedley, D | 2 |
| Oza, A | 2 |
| Siu, LL | 2 |
| Pond, GR | 3 |
| Moore, MJ | 2 |
| Ishii, H | 1 |
| Yonemoto, N | 1 |
| Nagase, M | 1 |
| Yoshino, M | 1 |
| Patt, YZ | 2 |
| Hassan, MM | 1 |
| Aguayo, A | 1 |
| Nooka, AK | 1 |
| Lozano, RD | 1 |
| Curley, SA | 1 |
| Vauthey, JN | 1 |
| Ellis, LM | 1 |
| Schnirer, II | 1 |
| Wolff, RA | 1 |
| Charnsangavej, C | 2 |
| Brown, TD | 1 |
| de Aretxabala, X | 2 |
| Losada, H | 1 |
| Mora, J | 1 |
| Roa, I | 2 |
| Burgos, L | 1 |
| Yáñez, E | 1 |
| Quijada, I | 1 |
| Marubashi, S | 1 |
| Dono, K | 1 |
| Takahashi, H | 1 |
| Hashimoto, K | 1 |
| Kubota, M | 1 |
| Yamamoto, S | 1 |
| Miyamoto, A | 1 |
| Nagano, H | 1 |
| Nakamori, S | 1 |
| Umeshita, K | 1 |
| Sakon, M | 1 |
| Monden, M | 1 |
| Takeda, Y | 1 |
| Hasuike, Y | 2 |
| Kashiwazaki, M | 1 |
| Tsujinaka, T | 1 |
| Soma, I | 1 |
| Hayashi, N | 1 |
| Fukuchi, N | 1 |
| Izawa, H | 1 |
| Yoshida, T | 2 |
| Ebisui, C | 1 |
| Sakita, I | 1 |
| Fujimoto, T | 1 |
| Koshino, T | 1 |
| Izumiyama, K | 1 |
| Al-Khatib, H | 1 |
| Mahoney, MR | 1 |
| Burgart, L | 1 |
| Cera, PJ | 1 |
| Flynn, PJ | 1 |
| Finch, TR | 1 |
| Levitt, R | 1 |
| Windschitl, HE | 1 |
| Knost, JA | 1 |
| Tschetter, LK | 1 |
| Seo, E | 1 |
| Abei, M | 1 |
| Wakayama, M | 1 |
| Fukuda, K | 1 |
| Ugai, H | 1 |
| Murata, T | 1 |
| Todoroki, T | 2 |
| Matsuzaki, Y | 1 |
| Tanaka, N | 1 |
| Hamada, H | 1 |
| Yokoyama, KK | 1 |
| Nakano, K | 1 |
| Todo, T | 1 |
| Zhao, G | 1 |
| Yamaguchi, K | 1 |
| Kuroki, S | 1 |
| Cohen, JB | 1 |
| Glorioso, JC | 1 |
| Tanaka, M | 2 |
| Feld, R | 1 |
| Chen, E | 1 |
| Nematollahi, M | 1 |
| Zhang, J | 1 |
| Czito, BG | 1 |
| Hurwitz, HI | 1 |
| Clough, RW | 1 |
| Tyler, DS | 1 |
| Morse, MA | 1 |
| Clary, BM | 1 |
| Pappas, TN | 1 |
| Fernando, NH | 1 |
| Willett, CG | 1 |
| Cho, JY | 1 |
| Nam, JS | 1 |
| Park, MS | 1 |
| Yu, JS | 1 |
| Paik, YH | 1 |
| Lee, SJ | 1 |
| Lee, DK | 1 |
| Yoon, DS | 1 |
| Shimada, Y | 1 |
| Matsumoto, G | 1 |
| Baba, H | 1 |
| Tsurta, K | 1 |
| Okamoto, A | 2 |
| Sugimoto, K | 1 |
| Ohzato, H | 1 |
| Tomita, N | 1 |
| Tamura, S | 1 |
| Aihara, T | 1 |
| Okamura, S | 1 |
| Miki, H | 1 |
| Nakata, K | 1 |
| Kim, C | 1 |
| Takiuchi, D | 1 |
| Okada, K | 1 |
| Takatsuka, Y | 1 |
| Kamisawa, T | 1 |
| Tu, Y | 1 |
| Egawa, N | 1 |
| Kobayashi, K | 1 |
| Tsuji, A | 2 |
| Morita, S | 3 |
| Horimi, T | 2 |
| Shirasaka, T | 2 |
| Kanematsu, T | 1 |
| Fan, YZ | 1 |
| Chen, CQ | 1 |
| Zhao, ZM | 1 |
| Sun, W | 1 |
| Berrios, M | 1 |
| Hepp, J | 1 |
| Gallardo, J | 1 |
| Cordova, A | 1 |
| Leon, J | 1 |
| Maluenda, F | 1 |
| Qayyum, A | 1 |
| Mujtaba, I | 1 |
| Riechelmann, RP | 1 |
| Townsley, CA | 1 |
| Chin, SN | 1 |
| Iyer, RV | 1 |
| Gibbs, J | 1 |
| Kuvshinoff, B | 1 |
| Fakih, M | 1 |
| Kepner, J | 1 |
| Soehnlein, N | 1 |
| Lawrence, D | 1 |
| Javle, MM | 1 |
| Smith, GW | 1 |
| Bukowski, RM | 1 |
| Hewlett, JS | 1 |
| Groppe, CW | 1 |
| Falkson, G | 1 |
| MacIntyre, JM | 1 |
| Buskirk, SJ | 1 |
| Adson, MA | 1 |
| Martinez, A | 1 |
| May, GR | 1 |
| McIlrath, DC | 1 |
| Edmundson, GK | 1 |
| Bender, CE | 1 |
| Martin, JK | 1 |
| Ichiki, AT | 1 |
| Krauss, S | 1 |
| Israelsen, KL | 1 |
| Sonoda, T | 1 |
| Collmann, IR | 1 |
| Hata, Y | 1 |
| Hisa, N | 1 |
| Fujiwara, Y | 1 |
| Higaki, T | 1 |
| Kamiike, O | 1 |
| Yoshida, D | 1 |
| Yoshida, S | 1 |
| Mishima, O | 1 |
| Sasaki, E | 1 |
| Takahashi, M | 1 |
| Uchino, J | 1 |
| Futakuchi, K | 1 |
| Nomura, Y | 1 |
| Kato, K | 1 |
| Koike, A | 1 |
| Koide, T | 1 |
| Kojima, T | 1 |
| Kawai, Y | 2 |
| Kuroda, H | 1 |
| Tanaka, K | 1 |
| Takeshige, K | 1 |
| Jones, DV | 1 |
| Hoque, A | 1 |
| Lozano, R | 1 |
| Markowitz, A | 1 |
| Raijman, I | 1 |
| Lynch, P | 1 |
| Gebbia, V | 1 |
| Majello, E | 1 |
| Testa, A | 1 |
| Pezzella, G | 1 |
| Giuseppe, S | 1 |
| Giotta, F | 1 |
| Riccardi, F | 1 |
| Fortunato, S | 1 |
| Colucci, G | 1 |
| Gebbia, N | 1 |
| Fukuda, S | 2 |
| Okuda, K | 1 |
| Kinoshita, H | 1 |
| Isomoto, H | 1 |
| Yokoyama, M | 1 |
| Takahashi, S | 1 |
| Tateoka, H | 1 |
| Ino, M | 1 |
| Takeuchi, S | 1 |
| Tanaka, T | 1 |
| Noda, H | 1 |
| Shirai, Y | 1 |
| Ohtani, T | 1 |
| Tsukada, K | 1 |
| Hatakeyama, K | 1 |
| Aoki, T | 2 |
| Tsuchida, A | 1 |
| Asami, K | 1 |
| Uda, O | 1 |
| Inoue, K | 1 |
| Masuhara, S | 1 |
| Kasuya, K | 1 |
| Ozawa, T | 1 |
| Koyanagi, Y | 1 |
| Kawabata, Y | 1 |
| Yano, S | 1 |
| Ohishi, T | 1 |
| Sumi, S | 1 |
| Nio, Y | 1 |
| Tamura, K | 1 |
| Hara, H | 1 |
| Nomura, E | 1 |
| Watanabe, I | 1 |
| Sako, S | 1 |
| Otani, M | 1 |
| Tanigawa, N | 1 |
| Maeda, T | 1 |
| Sano, O | 1 |
| Yamanaka, T | 1 |
| Beppu, T | 1 |
| Matsuda, T | 1 |
| Ogawa, M | 1 |
| Hara, Y | 2 |
| Kawasaki, T | 1 |
| Yabata, E | 1 |
| Gen, T | 1 |
| Jibiki, M | 1 |
| Kudoh, A | 1 |
| Noguchi, N | 1 |
| Kataoka, T | 1 |
| Teramoto, K | 1 |
| Iwai, T | 1 |
| Takasaki, M | 1 |
| Takamatsu, M | 1 |
| Takahashi, I | 1 |
| Kamata, T | 1 |
| Morita, A | 1 |
| Nakamoto, A | 1 |
| Onishi, I | 1 |
| Takeda, T | 1 |
| Koyasaki, N | 1 |
| Kanno, M | 1 |
| Ishizaki, M | 1 |
| Akiyama, N | 1 |
| Tanaka, S | 1 |
| Motegi, M | 1 |
| Sasamoto, H | 1 |
| Osawa, H | 1 |
| Wada, W | 1 |
| Nakajima, M | 1 |
| Ohta, K | 1 |
| Sawamura, A | 1 |
| Miyahara, E | 1 |
| Kim, R | 1 |
| Toge, T | 1 |
| Kresl, JJ | 1 |
| Schild, SE | 1 |
| Henning, GT | 1 |
| Donohue, J | 1 |
| Pitot, H | 1 |
| Nagorney, D | 1 |
| Madisch, A | 1 |
| Wiedbrauck, F | 1 |
| Marquard, F | 1 |
| Stolte, M | 1 |
| Hotz, J | 1 |
| Puhalla, H | 1 |
| Bareck, E | 1 |
| Scheithauer, W | 1 |
| Ploner, M | 1 |
| Stiglbauer, W | 1 |
| Depisch, D | 1 |
| De Jager, RL | 1 |
| Magill, GB | 1 |
| Golbey, RB | 1 |
| Krakoff, IH | 1 |
| Tobita, Y | 1 |
| Falk, RE | 1 |
| MacGregor, AB | 1 |
| Landi, S | 1 |
| Ambus, U | 1 |
| Langer, B | 1 |
| Sasaki, M | 1 |
| Yamauchi, H | 1 |
| Kajihara, T | 1 |
| Watanabe, G | 1 |
| Hanaue, H | 1 |
| Yoshida, K | 1 |
| Shimizu, T | 1 |
| Nozue, M | 1 |
| Ueda, H | 1 |
| Miyamoto, H | 1 |
| Iwasaki, Y | 1 |
| Loreggian, L | 1 |
| Zorat, PL | 1 |
| Lora, O | 1 |
| Fornasiero, A | 1 |
| Calzavara, F | 1 |
| Okada, S | 1 |
| Okazaki, N | 1 |
| Hasumura, S | 1 |
| Nagamori, S | 1 |
| Fujise, K | 1 |
| Homma, S | 1 |
| Sujino, H | 1 |
| Matsuura, T | 1 |
| Shimizu, K | 1 |
| Niiya, M | 1 |
| Kameda, H | 1 |
| Kairaluoma, MI | 1 |
| Leinonen, A | 1 |
| Niemelä, R | 1 |
| Kiviniemi, H | 1 |
| Siniluoto, T | 1 |
| Ståhlberg, M | 1 |
| Sakata, Y | 1 |
| Fukushi, G | 1 |
| Tsushima, K | 1 |
| Suzuki, H | 1 |
| Kimura, T | 1 |
| Kimura, M | 1 |
| Tamura, Y | 1 |
| Kishibe, T | 1 |
| Saitoh, S | 1 |
| Itoh, T | 1 |
| Garewal, H | 1 |
| Ahmann, FR | 1 |
| Hirabayashi, N | 1 |
| Nosoh, Y | 1 |
| Nishiyama, M | 1 |
| Yamaguchi, M | 1 |
| Yoshinaka, K | 1 |
| Niimoto, M | 1 |
| Hattori, T | 1 |
| Futorian, ES | 1 |
| Shubin, BM | 1 |
| Missale, G | 1 |
| Cocconi, G | 1 |
| Pettenati, V | 1 |
| Kobayashi, T | 1 |
| Takatani, O | 1 |
| Hattori, N | 1 |
| Kimura, K | 1 |
| Davis, HL | 1 |
| Ramirez, G | 1 |
| Ansfield, FJ | 1 |
| Sanderson, TA | 1 |
| McBride, CM | 1 |
| Gulesserian, HP | 1 |
| Lawton, RL | 1 |
| Condon, RE | 1 |
| Chevrel, B | 1 |
| Chevrel, JP | 1 |
| Pemberton, LB | 1 |
| Diffenbaugh, WF | 1 |
| Strohl, EL | 1 |
| Barrett, O | 1 |
| Cohen, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II Trial of Adjuvant Capecitabine/Gemcitabine Chemotherapy Followed By Concurrent Capecitabine and Radiotherapy in Extrahepatic Cholangiocarcinoma (EHCC)[NCT00789958] | Phase 2 | 105 participants (Actual) | Interventional | 2008-12-31 | Completed | ||
| A Randomized Controlled, Open Labeled, Two Arm, Study of Addition of Everolimus to Standard of Care in Carcinoma Gallbladder[NCT05833815] | Phase 2/Phase 3 | 56 participants (Anticipated) | Interventional | 2022-11-01 | Recruiting | ||
| Efficacy and Tolerance of RADIOEMBOLIZATION for Patients With Unresectable Intrahepatic Cholangiocarcinoma With Tumor Progression After First-line Therapy[NCT01383746] | Phase 1/Phase 2 | 5 participants (Actual) | Interventional | 2011-10-31 | Terminated (stopped due to Not enough inclusion) | ||
| Real-world Study for Targeted Therapy and Immunotherapy in Patients With Advanced Hepatobiliary Tumors: a Multi-centers, Open-assess Observational Study.[NCT03892577] | 3,000 participants (Anticipated) | Observational [Patient Registry] | 2017-07-01 | Recruiting | |||
| A Phase II Trial of Gemcitabine (NSC-613327) and Capecitabine (NSC-712807) in Patients With Unresectable or Metastatic Gallbladder or Cholangiocarcinoma[NCT00033540] | Phase 2 | 57 participants (Actual) | Interventional | 2003-09-30 | Completed | ||
| Randomized Controlled Trial Comparing Adjuvant Chemotherapy Vs. no Chemotherapy for Patients With Carcinoma of Gallbladder Undergoing Curative Resection.[NCT02778308] | 100 participants (Actual) | Interventional | 2012-01-31 | Completed | |||
| Randomized Phase 2 Study of Capecitabine vs Gemcistabine Plus Cisplatin in Patients With Resected Extrahepatic Cholangiocarcinoma With Regional Lymph Node Metastasis[NCT03079427] | Phase 2 | 101 participants (Actual) | Interventional | 2017-05-15 | Completed | ||
| Randomized Open-label Trial of Dose Dense, Fixed Dose Capecitabine Compared to Standard Dose Capecitabine in Metastatic Breast Cancer and Advanced/Metastatic Gastrointestinal Cancers.[NCT02595320] | Phase 2 | 200 participants (Actual) | Interventional | 2015-10-05 | Active, not recruiting | ||
| Phase II Trial Of Gemcitabine, 5-Fluorouracil, And Leucovorin In Patients With Measurable Unresectable Or Metastatic Biliary Tract Carcinoma (Intrahepatic, Extrahepatic, Ampulla Of Vater) And Gallbladder Carcinoma[NCT00009893] | Phase 2 | 42 participants (Actual) | Interventional | 2001-05-31 | Completed | ||
| A Phase 2 Study of Low-Dose Fractionated Radiation Therapy to the Whole Liver in Combination With Gemcitabine and Cisplatin in Locally Advanced Mass-Forming Intrahepatic Cholangiocarcinoma[NCT02254681] | Phase 2 | 6 participants (Actual) | Interventional | 2014-09-30 | Terminated (stopped due to lack of funding) | ||
| Oxaliplatin Plus Gemcitabine Versus Capecitabine Alone as Adjuvant Treatment in the Prevention of Recurrence of Intrahepatic Cholangiocarcinoma[NCT02548195] | Phase 3 | 286 participants (Anticipated) | Interventional | 2015-07-31 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Disease-free survival is calculated from date of registration to date of first documentation of relapse or death due to any cause. Patients last known to be alive are censored at date of last contact. (NCT00789958)
Timeframe: Up to 2 years from registration
| Intervention | percentage of participants (Number) |
|---|---|
| Adjuvant Chemotherapy + Chemoradiotherapy | 52 |
Local relapse is any evidence of new disease within the primary tumor bed or the regional (retroperitoneal, celiac, and portal vein nodes) lymphatics (these areas are to be encompassed within the radiation fields). (NCT00789958)
Timeframe: Up to 2 years from registration
| Intervention | percentage of participants (Number) |
|---|---|
| Adjuvant Chemotherapy + Chemoradiotherapy | 11 |
Time to death is calculated from date of registration to date of death due to any cause. Patients last known to be alive are censored at date of last contact. (NCT00789958)
Timeframe: Up to 2 years from registration
| Intervention | percentage of participants (Number) |
|---|---|
| Adjuvant Chemotherapy + Chemoradiotherapy | 65 |
Disease-free survival is calculated from date of registration to date of first documentation of relapse or death due to any cause. Patients last known to be alive are censored at date of last contact. (NCT00789958)
Timeframe: Up to 2 years from registration
| Intervention | percentage of participants (Number) |
|---|---|
| Patients With Negative Margins of Resection (R0) | 54 |
| Patients w/Microscopically Positive Margin of Resection (R1) | 48 |
Local relapse is any evidence of new disease within the primary tumor bed or the regional (retroperitoneal, celiac, and portal vein nodes) lymphatics (these areas are to be encompassed within the radiation fields). (NCT00789958)
Timeframe: Up to 2 years from registration
| Intervention | percentage of participants (Number) |
|---|---|
| Patients With Negative Margins of Resection (R0) | 9 |
| Patients w/Microscopically Positive Margin of Resection (R1) | 16 |
Time to death is calculated from date of registration to date of death due to any cause. Patients last known to be alive are censored at date of last contact. (NCT00789958)
Timeframe: Up to 2 years from registration
| Intervention | percentage of participants (Number) |
|---|---|
| Patients With Negative Margins of Resection (R0) | 67 |
| Patients w/Microscopically Positive Margin of Resection (R1) | 60 |
Only adverse events that are possibly, probably or definitely related to study drug are reported. (NCT00789958)
Timeframe: Up to 5 years
| Intervention | Participants (Number) | |||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Anorexia | Cardiac troponin I (cTnI) | Constipation | Dehydration | Diarrhea | Fatigue (asthenia, lethargy, malaise) | Febrile neutropenia | Hemoglobin | Hemorrhage, GI - Duodenum | Hemorrhage, GI - Lower GI NOS | Hypotension | Lung Infection w/normal ANC or Gr 1-2 neutrophils | Skin Infection w/normal ANC or Gr 1-2 neutrophils | Infection-Other (Specify) | Leukocytes (total WBC) | Lymphopenia | Mucositis/stomatitis (clinical exam) - Oral cavity | Neuropathy: sensory | Neutrophils/granulocytes (ANC/AGC) | Phosphate, serum-low (hypophosphatemia) | Platelets | Potassium, serum-low (hypokalemia) | Rash/desquamation | Rash: hand-foot skin reaction | Sodium, serum-low (hyponatremia) | Syncope (fainting) | Thrombosis/embolism (vascular access-related) | Thrombosis/thrombus/embolism | Ulcer, GI - Duodenum | Ventricular arrhythmia - Ventricular tachycardia | |
| Adjuvant Chemotherapy + Chemoradiotherapy | 1 | 1 | 1 | 1 | 6 | 4 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 5 | 6 | 2 | 1 | 35 | 1 | 2 | 2 | 1 | 10 | 1 | 1 | 1 | 1 | 1 | 1 |
Measured from time of registration to death, or last contact date (NCT00033540)
Timeframe: All patients will be followed until death or three years after registration, whichever is first.
| Intervention | months (Median) |
|---|---|
| Capecitabine + Gemcitabine | 7 |
Only eligible patients who received treatment were evaluable for response and survival outcomes. (NCT00033540)
Timeframe: 1-20 months
| Intervention | participants (Number) | |
|---|---|---|
| Eligible | Eligible and Analyzable | |
| Capecitabine + Gemcitabine | 54 | 52 |
To evaluate in a preliminary fashion relevant prognostic markers in gallbladder and cholangiocarcinoma which may have prognostic implications as predictors of survival. Overall survival measured from time of registration to death, or last contact date. (NCT00033540)
Timeframe: All patients will be followed until death or three years after registration, whichever is first.
| Intervention | months (Median) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TS 3' +/+ (N=14) | TS 3' +/- (N=6) | TS 3' -/- (N=2) | TS 5' Low functional significance (N=16) | TS 5' Intermediate functional significance (N=16) | MTHFR C677T - C/C (N=11) | MTHFR C677T - C/T (N=11) | MTHFR A1298C - A/A (N=11) | MTHFR A1298C - A/C (N=8) | MTHFR A1298C - C/C (N=3) | RRMI G/A - G/G (N=9) | RRMI G/A - G/A (N=10) | RRMI G/A - A/A (N=3) | CDA A79C - A/A (N=8) | CDA A79C - A/C (N=12) | CDA A79C - C/C (N=1) | |
| Capecitabine + Gemcitabine | 7 | 7 | 9 | 9 | 7 | 6 | 7 | 7 | 4 | 9 | 7 | 9 | 5 | 4 | 7 | NA |
Adverse Events (AEs) are reported by the NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0. Any CTCAE 3.0 event of Grade 3 (severe), Grade 4 (life threatening) or Grade 5 (fatal) which were deemed to be related to protocol treatment are included. For each patient, worst grade of each event type is reported. (NCT00033540)
Timeframe: Patients were assessed for adverse events 3 weeks after starting treatment. Assessments for adverse events continued every 3 weeks for the duration of protocol treatment.
| Intervention | Participants (Number) | |||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ALT, SGPT (serum glutamic pyruvic transaminase) | AST,SGOT (serum glutamic oxaloacetic transaminase) | Albumin, serum-low (hypoalbuminemia) | Alkaline phosphatase | Anorexia | Ascites (non-malignant) | Bilirubin (hyperbilirubinemia) | Constipation | Creatinine | Dehydration | Diarrhea | Dysphagia (difficulty swallowing) | Fatigue (asthenia, lethargy, malaise) | Hemoglobin | Hemolysis | Hemorrhage, GI - Esophagus | Infection w/Grade 3-4 neutrophils - Upper airway | Infection with normal ANC or Grade 1-2 neutrophils | Leukocytes (total WBC) | Mucositis/stomatitis (clinical exam) - Oral cavity | Mucositis/stomatitis (function/symp)-Oral cavity | Muscle weakness (not due to neuropathy) | Nausea | Neutrophils/granulocytes (ANC/AGC) | Pain - Abdomen NOS | Pain - Joint | Pain - Muscle | Pain - Tumor pain | Platelets | Potassium, serum-low (hypokalemia) | Rash: hand-foot skin reaction | Supraventricular nodal arrhythmia | Thrombosis/thrombus/embolism | Vomiting | |
| Gemcitabine and Capecitabine | 1 | 5 | 1 | 5 | 2 | 1 | 4 | 1 | 1 | 3 | 1 | 1 | 8 | 6 | 1 | 1 | 1 | 1 | 9 | 1 | 1 | 1 | 3 | 16 | 2 | 1 | 1 | 1 | 12 | 2 | 4 | 1 | 1 | 2 |
Complete Response (CR) is complete disappearance of all measurable and non-measurable disease. No new lesions, no disease related symptoms. Normalization of markers and other abnormal lab values. Partial Response (PR) is greater than or equal to 30% decrease under baseline of the sum of longest diameters of all target measurable lesions. No unequivocal progression of non-measurable disease. No new lesions. Confirmation of CR or PR means a repeat scan at least 4 weeks apart documented before progression or symptomatic deterioration. Progression is 20% increase in sum of longest diameters of target measurable lesions over smallest sum observed and/or unequivocal progression of non-measurable disease and/or appearance of new lesion/site or death due to disease without prior documentation of progression and without symptomatic deterioration. Symptomatic deterioration is global deterioration of health status requiring discontinuation of treatment without objective evidence of progression. (NCT00033540)
Timeframe: Patients assessed at least every six weeks while on protocol treatment
| Intervention | participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Confirmed Partial Response | Unconfirmed Partial Response | Stable Disease | Progression | Symptomatic Deterioration | Early Death | Inadequate Assessment | |
| Capecitabine + Gemcitabine | 7 | 6 | 12 | 15 | 3 | 1 | 8 |
To determine the number of participants with Intrahepatic disease progression assessed by MRI of the abdomen with intravenous gadolinium contrast using RECIST criteria. (NCT02254681)
Timeframe: From date of first treatment until date of first documented progression or date of death from any cause, which ever comes first, assessed up to 24 months.
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment | 6 |
To determine the number of participants with Intrahepatic recurrence assessed by RECIST criteria using MRI of the abdomen with intravenous gadolinium contrast. (NCT02254681)
Timeframe: From date of partial hepatectomy until date of first documented recurrence or date of death from any cause, assessed up to 24 months.
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment | 1 |
Measured post-operative complications include (but not limited to) bile leak, liver failure, ascites, infection, any organ failure or insufficiency, venous thromboembolism, and mortality. (NCT02254681)
Timeframe: up to 90 days after partial hepatectomy
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment | 1 |
12 reviews available for fluorouracil and Cancer of Gallbladder
| Article | Year |
|---|---|
Update on Chemoresistance Mechanisms to First-Line Chemotherapy for Gallbladder Cancer and Potential Reversal Strategies.
Topics: Cisplatin; Drug Resistance, Neoplasm; Fluorouracil; Gallbladder Neoplasms; Gemcitabine; Humans | 2023 |
The efficacy and safety of 5-fluorouracil based adjuvant therapy in resected biliary tract cancer: A systematic review and meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Bilia | 2022 |
The role of capecitabine in the management of tumors of the digestive system.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms | 2009 |
[Chemotherapy in gallbladder carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Capecitabine; Cisplatin; Deoxyc | 2010 |
Adjuvant chemotherapy for resectable biliary tract cancer: current status and future direction.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Biliary Tract Neoplasms; Chemotherapy, Adjuv | 2012 |
Role of chemotherapy in treatments for biliary tract cancer.
Topics: Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Cisp | 2012 |
[A long survival after the treatment of a squamous cell carcinoma of the gallbladder].
Topics: Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Chemoradiotherapy, Adjuvant; Cholecystect | 2013 |
Carcinoma of the gallbladder.
Topics: Algorithms; Antimetabolites, Antineoplastic; Cholecystectomy; Fluorouracil; Gallbladder Neoplasms; H | 2003 |
[A case of liver metastasis from gallbladder cancer with marked response to arterial infusion chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cholecystectomy; Cisplatin; Combined Modality | 2003 |
[Thermo-chemo-radiotherapy for advanced biliary carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Cisplatin; Combined Modality Th | 2006 |
Chemoradiotherapy in gallbladder cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neopl | 2006 |
[A case of unresectable advanced gall bladder cancer successfully treated by hepatic arterial chemotherapy with reservoir (HACR) using CDDP and 5-FU].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Female; Flu | 1999 |
24 trials available for fluorouracil and Cancer of Gallbladder
| Article | Year |
|---|---|
Efficacy of Capecitabine Plus Irinotecan vs Irinotecan Monotherapy as Second-line Treatment in Patients With Advanced Gallbladder Cancer: A Multicenter Phase 2 Randomized Clinical Trial (GB-SELECT).
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; | 2021 |
SWOG S0809: A Phase II Intergroup Trial of Adjuvant Capecitabine and Gemcitabine Followed by Radiotherapy and Concurrent Capecitabine in Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; | 2015 |
SWOG S0809: A Phase II Intergroup Trial of Adjuvant Capecitabine and Gemcitabine Followed by Radiotherapy and Concurrent Capecitabine in Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; | 2015 |
SWOG S0809: A Phase II Intergroup Trial of Adjuvant Capecitabine and Gemcitabine Followed by Radiotherapy and Concurrent Capecitabine in Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; | 2015 |
SWOG S0809: A Phase II Intergroup Trial of Adjuvant Capecitabine and Gemcitabine Followed by Radiotherapy and Concurrent Capecitabine in Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; | 2015 |
Gemcitabine, oxaliplatin and 5-FU in advanced bile duct and gallbladder carcinoma: two parallel, multicentre phase-II trials.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Deoxy | 2009 |
Efficacy and safety of capecitabine in combination with docetaxel and mitomycin C in patients with pre-treated pancreatic, gallbladder, and bile duct carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Ne | 2010 |
Best supportive care compared with chemotherapy for unresectable gall bladder cancer: a randomized controlled study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Drug Administr | 2010 |
A phase II trial of gemcitabine and capecitabine in patients with unresectable or metastatic gallbladder cancer or cholangiocarcinoma: Southwest Oncology Group study S0202.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; | 2011 |
Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Chemotherapy, Adju | 2002 |
Prospective evaluation of efficacy and toxicity of 5-fu and folinic acid (Mayo Clinic regimen) in patients with advanced cancer of the gallbladder.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Female; Fluorouracil; Gallbladder Neoplasms; Humans | 2003 |
Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced biliary cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplas | 2003 |
Gemcitabine concurrent with continuous infusional 5-fluorouracil in advanced biliary cancers: a review of the Princess Margaret Hospital experience.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bi | 2004 |
Gemcitabine, 5-fluorouracil, and leucovorin in advanced biliary tract and gallbladder carcinoma: a North Central Cancer Treatment Group phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms | 2005 |
Gemcitabine, 5-fluorouracil, and leucovorin in advanced biliary tract and gallbladder carcinoma: a North Central Cancer Treatment Group phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms | 2005 |
Gemcitabine, 5-fluorouracil, and leucovorin in advanced biliary tract and gallbladder carcinoma: a North Central Cancer Treatment Group phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms | 2005 |
Gemcitabine, 5-fluorouracil, and leucovorin in advanced biliary tract and gallbladder carcinoma: a North Central Cancer Treatment Group phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms | 2005 |
Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemot | 2005 |
A Phase II study of capecitabine combined with gemcitabine in patients with advanced gallbladder carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Female; Fl | 2005 |
A phase II study of LFP therapy (5-FU (5-fluorourasil) continuous infusion (CVI) and Low-dose consecutive (Cisplatin) CDDP) in advanced biliary tract carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Carcinoma; Cisplatin; Dos | 2006 |
Expanded phase II trial of gemcitabine and capecitabine for advanced biliary cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Comb | 2007 |
A phase II study of gemcitabine and capecitabine in advanced cholangiocarcinoma and carcinoma of the gallbladder: a single-institution prospective study.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct N | 2007 |
Eastern Cooperative Oncology Group experience with chemotherapy for inoperable gallbladder and bile duct cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Clinical Trials as Topic; Femal | 1984 |
[Evaluation of arterial infusion chemotherapy for advanced gallbladder cancer using implantable port].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Epirubicin; Fema | 1994 |
Phase II trial of intravenous flourouracil and subcutaneous interferon alfa-2b for biliary tract cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Biliary Tract Neop | 1996 |
Treatment of advanced adenocarcinomas of the exocrine pancreas and the gallbladder with 5-fluorouracil, high dose levofolinic acid and oral hydroxyurea on a weekly schedule. Results of a multicenter study of the Southern Italy Oncology Group (G.O.I.M.).
Topics: Adenocarcinoma; Administration, Oral; Aged; Antidotes; Antimetabolites, Antineoplastic; Antineoplast | 1996 |
[Preliminary clinical evaluation of low-dose CDDP and continuous 5-FU therapy for advanced gallbladder cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Drug | 2000 |
[Biweekly low-dose cisplatin and 5-fluorouracil combination chemotherapy for advanced gastrointestinal carcinoma].
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; | 2000 |
[Prospective randomized trial comparing modified FAM (5-fluorouracil (5-FU) + adriamycin + mitomycin C) versus 5-FU alone for the treatment of non-resectable pancreatic and biliary tract carcinomas (the 1st trial in non-resectable patients). Study Group o
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Chemotherapy, | 1992 |
Superselective intra-arterial chemotherapy with mitomycin C in liver and gallbladder cancer.
Topics: Colonic Neoplasms; Combined Modality Therapy; Female; Fluorouracil; Gallbladder Neoplasms; Humans; I | 1988 |
91 other studies available for fluorouracil and Cancer of Gallbladder
| Article | Year |
|---|---|
MiR-335 promotes cell proliferation by inhibiting MEF2D and sensitizes cells to 5-Fu treatment in gallbladder carcinoma.
Topics: Cell Proliferation; Cell Survival; Female; Fluorouracil; Gallbladder Neoplasms; Humans; Male; MEF2 T | 2019 |
Effect of Adjuvant Gemcitabine Combined with Low-dose 5-Fluorouracil and Cisplatin Chemotherapy for Advanced Biliary Carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Chemotherapy, Adjuvant; C | 2017 |
Guided chemotherapy based on patient-derived mini-xenograft models improves survival of gallbladder carcinoma patients.
Topics: Aged; Aged, 80 and over; Animals; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fem | 2018 |
Pretreatment with Gemcitabine/5-Fluorouracil Enhances the Cytotoxicity of Trastuzumab to HER2-Negative Human Gallbladder Cancer Cells In Vitro and In Vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Deoxycytidine; Female; Fluoroura | 2019 |
Radiotherapy or Chemoradiation in Unresectable Biliary Cancer: A Retrospective Study.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Brachytherapy; | 2019 |
Bcl-2 gene silencing by RNA interference inhibits the growth of the human gallbladder carcinoma cell line GBC-SD in vitro and in vivo.
Topics: Animals; Apoptosis; Carcinogenesis; Cell Growth Processes; Cell Line, Tumor; Fluorouracil; Gallbladd | 2013 |
FOLFIRI in patients with locally advanced or metastatic pancreatic or biliary tract carcinoma: a monoinstitutional experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neopla | 2013 |
Cordycepin down-regulates multiple drug resistant (MDR)/HIF-1α through regulating AMPK/mTORC1 signaling in GBC-SD gallbladder cancer cells.
Topics: AMP-Activated Protein Kinases; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Deoxyadenosines; | 2014 |
Advanced biliary tract carcinomas: a retrospective multicenter analysis of first and second-line chemotherapy.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Duct | 2014 |
Hispidulin inhibits proliferation and enhances chemosensitivity of gallbladder cancer cells by targeting HIF-1α.
Topics: Animals; Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; | 2015 |
Intraarterial 5-fluorouracil and interferon therapy is safe and effective for nonresectable biliary tract adenocarcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; | 2015 |
Three-weekly oxaliplatin combined with gemcitabine and capecitabine in the first-line treatment of patients with advanced biliary tract cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Ducts, Extrahep | 2015 |
Use of gemcitabine-platinum in Indian patients with advanced gall bladder cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Deoxycytidine; | 2015 |
FOLFOX-4 as second-line therapy after failure of gemcitabine and platinum combination in advanced gall bladder cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Fem | 2016 |
Is There a Role for Adjuvant Therapy in R0 Resected Gallbladder Cancer?: A Propensity Score-Matched Analysis.
Topics: Aged; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Combined Modality Therapy; Disease-Free S | 2016 |
Inhibition of mTOR suppresses human gallbladder carcinoma cell proliferation and enhances the cytotoxicity of 5-fluorouracil by downregulating MDR1 expression.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; Cell Line, Tumor; Cell Proliferation; Fluoro | 2016 |
Genetic alteration of Keap1 confers constitutive Nrf2 activation and resistance to chemotherapy in gallbladder cancer.
Topics: Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Cell Line, Tumor; DNA, Complementary; Down | 2008 |
Gallbladder cancer (GBC): 10-year experience at Memorial Sloan-Kettering Cancer Centre (MSKCC).
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Chemotherapy, Adjuvan | 2008 |
Successful treatment of advanced gallbladder cancer with an anticancer drug S-1: assessment based on intratumoral gene.
Topics: Antimetabolites, Antineoplastic; Dihydrouracil Dehydrogenase (NADP); Drug Combinations; Female; Fluo | 2008 |
[Elderly patient with metastatic gallbladder cancer treated by cisplatin, epirubicin and continuous infusion 5-fluorouracil].
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cisplatin; Epi | 2008 |
Adjuvant therapy for gallbladder carcinoma: the Mayo Clinic Experience.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Analysis of Variance; Carc | 2009 |
Thymidylate synthase and dihydropyrimidine dehydrogenase are upregulated in pancreatic and biliary tract cancers.
Topics: Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Biliary Tract Neoplasms; Dihydrouracil Dehydro | 2009 |
Gallbladder squamous cell carcinoma in the setting of low-dose methotrexate use.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cholecystectomy, Lap | 2009 |
Treatment of biliary tract cancer with NVP-AEW541: mechanisms of action and resistance.
Topics: Antineoplastic Agents; Biliary Tract Neoplasms; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; | 2010 |
Time to move to targeted drugs in biliary tract cancer?
Topics: Adenocarcinoma; Ampulla of Vater; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineo | 2010 |
Preliminary experience of cetuximab in the treatment of advanced-stage biliary tract cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2010 |
Outcome of patients receiving chemotherapy for advanced biliary tract or gallbladder carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neopla | 2010 |
Survival of a cohort of patients with intermediate and advanced gall bladder cancer treated with a prospective therapeutic protocol.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma; Chemotherapy, Adjuvant; Chile; Cho | 2010 |
Adjuvant chemoradiation therapy in gallbladder cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Cisplati | 2010 |
CD44+ CD133+ population exhibits cancer stem cell-like characteristics in human gallbladder carcinoma.
Topics: AC133 Antigen; Animals; Antigens, CD; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Fe | 2010 |
Evaluation of two modified ECF regimens in the treatment of advanced gallbladder cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Evaluation; Epirubicin; | 2011 |
Outcomes of radical surgery for gallbladder cancer patients with lymphatic metastases.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chi-Square Distribut | 2011 |
Adjuvant radio-chemotherapy after extended or simple cholecystectomy in gallbladder cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Capec | 2011 |
Postoperative chemoradiotherapy for gallbladder cancer.
Topics: Adenocarcinoma; Adult; Aged; Chemoradiotherapy; Female; Fluorouracil; Gallbladder Neoplasms; Humans; | 2012 |
Capecitabine plus cisplatin as first-line chemotherapy for advanced biliary tract cancer: a retrospective single-center study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bile Duct Neoplasms; Bi | 2012 |
Fluoropyrimidines plus cisplatin versus gemcitabine/gemcitabine plus cisplatin in locally advanced and metastatic biliary tract carcinoma - a retrospective study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; | 2012 |
Improvement of prognosis for unresectable biliary tract cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biliary Tract Neoplasms; Deoxycytidine; Disea | 2013 |
[A case of recurrent gallbladder cancer responding to low-dose 5-FU and CDDP therapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dose-Response Relationshi | 2002 |
Palliative chemotherapy with gemcitabine and weekly high-dose 5-fluorouracil as 24-h infusion in metastatic biliary tract and gall bladder adenocarcinomas.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Deoxy | 2003 |
VINCRISTINE (NSC-67574) THERAPY OF ADULT PATIENTS WITH SOLID TUMORS.
Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoid Tumor; Carcinoma, Bronchogenic; Carcinoma, Squamous | 1964 |
FLUORINATED PYRIMIDINE THERAPY OF ADVANCED GASTROINTESTINAL CANCER.
Topics: Alopecia; Colonic Neoplasms; Drug Eruptions; Esophagitis; Fluorouracil; Gallbladder Neoplasms; Human | 1964 |
Chemotherapy in the treatment of advanced gallbladder cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Do | 2004 |
Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma.
Topics: Administration, Oral; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Capecitabine; Carcinoma, Hepato | 2004 |
Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma.
Topics: Administration, Oral; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Capecitabine; Carcinoma, Hepato | 2004 |
Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma.
Topics: Administration, Oral; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Capecitabine; Carcinoma, Hepato | 2004 |
Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma.
Topics: Administration, Oral; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Capecitabine; Carcinoma, Hepato | 2004 |
[Neoadjuvant chemoradiotherapy in gallbladder cancer].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Combined Modality Therapy; Fem | 2004 |
[A case of successful treatment with combined 5-fluorouracil, adriamycin, cisplatin (FAP) therapy followed by Gemcitabine, UFT therapy and intra-arterial FAP therapy for unresectable advanced gallbladder cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Doxorubicin; Female; Fluor | 2004 |
[Adjuvant arterial infusion chemotherapy for patients with biliary cancer].
Topics: Adult; Aged; Aged, 80 and over; Ampulla of Vater; Bile Duct Neoplasms; Biliary Tract Neoplasms; Chem | 2004 |
[A case report--Efficacy of combination therapy to unresectable advanced gall bladder carcinoma--palliative operation, hepatic arterial infusion therapy, and radiation therapy].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Combined | 2004 |
Effective gene therapy of biliary tract cancers by a conditionally replicative adenovirus expressing uracil phosphoribosyltransferase: significance of timing of 5-fluorouracil administration.
Topics: Adenocarcinoma; Adenoviridae; Animals; Female; Fluorouracil; Gallbladder Neoplasms; Genetic Therapy; | 2005 |
Enhanced efficacy of conditionally replicating herpes simplex virus (G207) combined with 5-fluorouracil and surgical resection in peritoneal cancer dissemination models.
Topics: Animals; Antibodies, Viral; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Combined Modality | 2005 |
Adjuvant external-beam radiotherapy with concurrent chemotherapy after resection of primary gallbladder carcinoma: a 23-year experience.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antimetabolites, Antineoplastic; Chemotherapy, | 2005 |
[Two cases of advanced gallbadder cancer with para-aortic lymph node metastasis responding to intra-aortic infusion of gemcitabine and low-dose CDDP/5-FU].
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Cisplatin; Deoxycytidine; Drug Administration | 2005 |
[Two cases of successful local control with intermittent hepatic arterial infusion therapy using 5-FU and external radiation therapy for unresectable advanced gall bladder cancer].
Topics: Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Fluorouracil; Gallbladder Neoplasm | 2005 |
[Effects of norcantharidin on angiogenesis of human gallbladder carcinoma and its anti-angiogenic mechanisms].
Topics: Angiostatins; Animals; Antimetabolites, Antineoplastic; Apoptosis; Bridged Bicyclo Compounds, Hetero | 2006 |
Effects of chemotherapy on patients with unresectable or metastatic adenocarcinoma of gallbladder.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Fem | 2007 |
Hepatic artery infusion of 5-fluorouracil and mitomycin C in cholangiocarcinoma and gallbladder carcinoma.
Topics: Adenoma, Bile Duct; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms | 1984 |
Analysis of failure following curative irradiation of gallbladder and extrahepatic bile duct carcinoma.
Topics: Adult; Aged; Bile Duct Neoplasms; Brachytherapy; Combined Modality Therapy; Electrons; Female; Fluor | 1984 |
Sequential carcinoembryonic antigen levels. A predictor of response and relapse in combination chemotherapy of advanced gastrointestinal cancer.
Topics: Adenocarcinoma; Carcinoembryonic Antigen; Colonic Neoplasms; Drug Therapy, Combination; Fluorouracil | 1981 |
[The two cases of examination of chemotherapy in advanced gallbladder carcinoma].
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; | 1994 |
[Efficacy of 48-hour infusion of 5-fluorouracil for gall bladder cancer].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 1993 |
[Study of hepatic arterial chemoinfusion with continuous CDDP, 5-FU low dose administration for advanced gallbladder cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule | 1996 |
[A case of recurrent gallbladder cancer with marked response to arterial infusion chemotherapy and transarterial embolization].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cholecystectomy; Cisplatin; Drug Administration Sche | 1997 |
Lymph node recurrence of gallbladder carcinoma successfully managed by systemic chemotherapy with 5-fluorouracil and mitomycin C: report of a 5-year survivor.
Topics: Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemothe | 1997 |
[Aortic stop flow and hypoxic perfusion chemotherapy for unresectable gallbladder cancer].
Topics: Anesthesia, General; Antineoplastic Combined Chemotherapy Protocols; Aorta, Abdominal; Chemotherapy, | 1998 |
[A case of advanced gallbladder cancer responding to neoadjuvant intra-arterial chemotherapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy | 1999 |
Advanced gallbladder carcinoma with liver metastasis showing a favorable response after intra-arterial infusion chemotherapy: report of a case.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cisplatin; | 1999 |
[A case of unresectable gallbladder cancer responding to combination therapy with hyperthermia and local chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Femal | 2000 |
[Long-term survival of a patient with postoperative liver metastasis of stage IVa gallbladder cancer responding to hepatic arterial infusion chemotherapy].
Topics: Adenocarcinoma; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; C | 2001 |
[A case of inoperable advanced gall bladder cancer responding to intra-arterial infusion of 5-fluorouracil (5-FU) and leucovorin (LV)].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedul | 2001 |
Adjuvant external beam radiation therapy with concurrent chemotherapy in the management of gallbladder carcinoma.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Carcinoma, Adenosquamous; Female; Fluorouraci | 2002 |
[5-Fluorouracil-induced colitis--a review based upon consideration of 6 cases].
Topics: Aged; Colitis; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; | 2002 |
[Therapy of gallbladder carcinoma. Experience of a central hospital].
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antine | 2002 |
Combination chemotherapy with mitomycin C, 5-fluorouracil, and cytosine arabinoside in gastrointestinal cancer.
Topics: Adult; Aged; Cytarabine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Fluoro | 1976 |
[Digestive tract cancer: planning of chemotherapy].
Topics: Bile Duct Neoplasms; Cytarabine; Drug Therapy, Combination; Fluorouracil; Gallbladder Neoplasms; Hum | 1975 |
Immunostimulation with intraperitoneally administered bacille Calmette Guérin for advanced malignant tumors of the gastrointestinal tract.
Topics: Adult; Aged; BCG Vaccine; Bile Duct Neoplasms; Carcinoma; Colonic Neoplasms; Cyclophosphamide; Femal | 1976 |
[5-fluorouracil concentration in gastroenterological tumor tissues, in adjacent normal tissues, and in serum after preoperative oral administration of 5'-deoxy-5-fluorouridine (5'-DFUR)].
Topics: Administration, Oral; Colonic Neoplasms; Floxuridine; Fluorouracil; Gallbladder Neoplasms; Humans; S | 1991 |
[Neoplasms of the gallbladder and the extrahepatic bile ducts: radio-chemotherapeutic combined treatment. Results in 18 treated cases].
Topics: Adult; Aged; Bile Duct Neoplasms; Clinical Protocols; Combined Modality Therapy; Female; Fluorouraci | 1991 |
[Chemotherapy in cancers of the gallbladder and bile ducts].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cytarabine; | 1991 |
[Combination therapy of hyperthermia and other methods in liver and bile tract cancers--evaluation of these methods using cancer cell lines in vitro].
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line; Combined Modality Therapy; Doxorubicin; | 1989 |
[MQF-FT and MQF-UFT in gallbladder and bile duct cancer].
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Car | 1988 |
Failure of allopurinol to provide clinically significant protection against the hematologic toxicity of a bolus 5-FU schedule.
Topics: Adenocarcinoma; Adult; Allopurinol; Carcinoma, Squamous Cell; Colonic Neoplasms; Drug Administration | 1986 |
[Comparison of human tumor clonogenic and nude mouse-isotope assays in anticancer-agent sensitivity tests].
Topics: Animals; Breast Neoplasms; Colony-Forming Units Assay; Cyclophosphamide; Doxorubicin; Drug Evaluatio | 1985 |
[Selection of a method for treating cancer of the pancreaticoduodenal region].
Topics: Bile Duct Neoplasms; Cyclophosphamide; Duodenal Neoplasms; Fluorouracil; Gallbladder Neoplasms; Huma | 1971 |
[Comparison of several different methods of antiblastic therapy in advanced carcinomas of the digestive system].
Topics: Antineoplastic Agents; Bleomycin; Cyclophosphamide; Drug Therapy, Combination; Esophageal Neoplasms; | 1974 |
Echographic evaluation of abdominal tumor regression during antineoplastic treatment.
Topics: Abdominal Neoplasms; Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Cyclophosphamide; Doxorub | 1974 |
Combination chemotherapy in gastrointestinal cancer.
Topics: Adenocarcinoma; Adult; Alopecia; Appendiceal Neoplasms; Diarrhea; Drug Eruptions; Fluorouracil; Gall | 1970 |
Adenocarcinomas of stomach, pancreas, liver, and biliary tracts. Survival of 328 patients treated with fluoropyrimidine therapy.
Topics: Adenocarcinoma; Antineoplastic Agents; Bile Duct Neoplasms; Evaluation Studies as Topic; Floxuridine | 1974 |
Experience with hepatic arterial infusions.
Topics: Adult; Aged; Bile Duct Neoplasms; Carcinoma, Hepatocellular; Female; Floxuridine; Fluorouracil; Gall | 1971 |
Hepatic artery ligation and cytotoxic infusion in treatment of liver metastases.
Topics: Aged; Alkaline Phosphatase; Female; Fluorouracil; Gallbladder Neoplasms; Hepatic Artery; Humans; Inj | 1972 |
[Gallbladder cancer].
Topics: Adenocarcinoma; Adenoma; Carcinoma; Cholelithiasis; Fluorouracil; Gallbladder Neoplasms; Humans; Mel | 1971 |
The surgical significance of carcinoma of the gallbladder.
Topics: Appendicitis; Autopsy; Cholecystectomy; Cholecystitis; Cholelithiasis; Cholestasis; Diagnosis, Diffe | 1971 |
Liver regeneration after major hepatectomy. Effect of chemotherapy on growth and function--case report.
Topics: Adenocarcinoma; Female; Fluorouracil; Gallbladder Neoplasms; Gold Isotopes; Hepatectomy; Humans; Liv | 1968 |